ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Curt, Ozols, Brown Leaving NCI; More DCT Staff Changes

June 10, 1988

In Brief: Moffitt Gets $100M From Fla. For Construction; Two Head And Neck Surgical Societies Merge

July 3, 1998

FDA’s Oncologic Drugs Advisory Committee recommended approval of three drugs for cancer, voted down one.

September 16, 2005

FY’78 Construction Requests $44 Million, Budget At $12 Million

December 2, 1977

In Brief: NCFA Offers Grants For Research On Impact Of DRGs; ACCC Leaders Dispute HCFA Chief

March 8, 1985

FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response

July 29, 2011